Dr Banibrata Mukhopadhyay, M. Sc. Ph.D. - Visva Bharati University/ Muljibhai Patel Society for Research in Nephro Urology - Consultant Biochemist

Dr Banibrata Mukhopadhyay

M. Sc. Ph.D.

Visva Bharati University/ Muljibhai Patel Society for Research in Nephro Urology

Consultant Biochemist

Nadiad, Gujarat | India

Main Specialties: Chemistry

Additional Specialties: Clinical Chemistry


Top Author

Dr Banibrata Mukhopadhyay, M. Sc. Ph.D. - Visva Bharati University/ Muljibhai Patel Society for Research in Nephro Urology - Consultant Biochemist

Dr Banibrata Mukhopadhyay

M. Sc. Ph.D.

Introduction

With a chemistry background in graduate study I completed my MSC and PhD in Biochemistry for Bengal, India. Joined thereafter, in a state of the art automated laboratory at Gujarat that runs round the clock. It caters to the need of renal transplantation with dialysis facilities and nephro urology treatments.

As a part of my teaching schedules for the post PG DNB courses in Nephrology and Urology I participate in all laboratory based research activities. My present research field includes the study of non transferrin bound iron in blood and its impact on cardiovascular and renal diseases. Apart form routine clinical diagnostics the teaching and research activities here is the most enjoyable and disciplined works for a long time.

Utility of my hard earned education for the benefit of medical science as well as for the patients and society has provided me enough of reason to feel happy in daily life always. I welcome all others in the field who are interested in future too.

Primary Affiliation: Visva Bharati University/ Muljibhai Patel Society for Research in Nephro Urology - Nadiad, Gujarat , India

Specialties:

Additional Specialties:

Research Interests:


View Dr Banibrata Mukhopadhyay’s Resume / CV

Education

May 1995
Visva Bharati University
Ph.D.
Reproductive Endocrinology
Jun 1987
Kalyani University
M.Sc
Biochemistry

Experience

Jun 1996
Clinical Diagnostics and Research
Consultant Biochemsit
Muljibhai Patel Socity for Research in Nephro Urology

Publications

12Publications

280Reads

2Profile Views

35PubMed Central Citations

Iron, Hepcidin, and Death in Human AKI.

J Am Soc Nephrol 2019 03 8;30(3):493-504. Epub 2019 Feb 8.

Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2018100979DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405140PMC
March 2019
30 Reads
9.343 Impact Factor

Catalytic iron in acute myocardial infarction complicated by cardiogenic shock - A biomarker substudy of the IABP-SHOCK II-trial.

Int J Cardiol 2017 Jan 9;227:83-88. Epub 2016 Nov 9.

Department of Internal Medicine II, Cardiology/Angiology/Intensive Care Medicine, University Heart Center Lübeck, Lübeck, Germany; German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01675273163351
Publisher Site
http://dx.doi.org/10.1016/j.ijcard.2016.11.072DOI Listing
January 2017
46 Reads
1 Citation
4.040 Impact Factor

Catalytic Iron in acute Myocardial infarction complicated by cardiogenic shock-A biomarker substudyof the IABP-ShockII Trial.

International Journal of Cardiology

Background: Catalytic iron (CI) is unbound ferric iron with the potential to generate reactive oxygen specieswith further deleterious vascular effects. In acute coronary syndromes, high levels of CI are linked to all-causemortality. The prognostic impact of CI and ironmetabolismin cardiogenic shock (CS) is currently undetermined. Aims of this study were to investigate the prognostic impact of CI and to identify predictors of high CI levels in patients with CS complicating acute myocardial infarction. Methods: The Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial randomized 600 patients with CS to either therapy with intraaortic balloon pump or control. In 185 of these patients, blood samples were systematically collected at baseline and day 3. CI levelsweremeasured using amodified bleomycin detectable iron assay. Furthermore, levels of free hemoglobin, total serum iron, transferrin, total iron binding capacity, ferritin, hepcidin, and transferrin saturation were assessed. Results: Patients with baseline CI levels in the highest quartile had a worse outcome in comparison to patients with lower CI (day 1: HR 1.91 [1.11–3.31], p = 0.005; day 3: HR 2.15 [1.06–4.34], p = 0.01). In multivariable Cox-regression analysis baseline CI remained an independent predictor of 30-day mortality (HR per 10LOG 2.08 [1.25–3.47], p=0.005). Predictors of CI levels on day 3 were baseline CI, bleeding events, and baseline troponin T. Conclusions: CI levels were associated with increased short-term mortality in CS complicating acute myocardial infarction. High levels of CI at day 3 were associated with bleeding and high troponin levels.

View Article
November 2016
10 Reads

Increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery.

Kidney Int 2015 May 7;87(5):1046-54. Epub 2015 Jan 7.

Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ki.2014.374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137505PMC
May 2015
34 Reads
8 Citations
8.563 Impact Factor

Plasma catalytic iron, AKI, and death among critically ill patients.

Clin J Am Soc Nephrol 2014 Nov 4;9(11):1849-56. Epub 2014 Sep 4.

Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2215/CJN.02840314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220757PMC
November 2014
27 Reads
4 Citations
4.613 Impact Factor

Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.

Clin Cardiol 2013 Mar 3;36(3):139-45. Epub 2013 Feb 3.

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/clc.22089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649497PMC
March 2013
25 Reads
5 Citations
2.230 Impact Factor

Association of catalytic iron with cardiovascular disease.

Am J Cardiol 2012 Feb 8;109(3):438-42. Epub 2011 Nov 8.

Department of Nephrology, Muljibhai Patel Urological Hospital, Nadiad, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2011.09.032DOI Listing
February 2012
23 Reads
9 Citations
3.280 Impact Factor

Urinary catalytic iron in obesity.

Clin Chem 2011 Feb 28;57(2):272-8. Epub 2010 Dec 28.

Tulane University Health Sciences Center, New Orleans, Louisiana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2010.154757DOI Listing
February 2011
17 Reads
2 Citations
7.911 Impact Factor

Enzymuria pattern in early post renal transplant period: Diagnostic usefulness in graft dysfunction.

Indian J Clin Biochem 2004 Jul;19(2):14-9

Department of Biochemistry, Muljibhai Patel Urological Hospital, 387 001 Nadiad, Gujarat India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF02894251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454189PMC
July 2004
33 Reads
1 Citation